-
DEVELOPMENT OF A COMPOSITE ENDPOINT IN HYPOPHOSPHATASIA TO OPTIMIZE COST-EFFECTIVENESS DEMONSTRATION
Mar 18, 2026, 21:38 PM -
AFFORDABILITY OF PEDIATRIC DRUGS THROUGH CHINA’S NATIONAL DRUG PRICE NEGOTIATION: 2017-2024
Mar 18, 2026, 21:38 PM -
UNDERSTANDING CEA CHARACTERISTICS ASSOCIATED WITH COST-SAVING FINDINGS
Mar 18, 2026, 21:38 PM -
DEVELOPMENT AND VALIDATION OF AN ALGORITHM TO IDENTIFY ASPIRIN USE FROM ELECTRONIC MEDICAL RECORDS AND CLAIMS DATA
Mar 18, 2026, 21:38 PM -
US MEDICINE PRICING POLICY CHANGES: IMPACT ON THE FULL BIOPHARMACEUTICAL INVESTMENT ECOSYSTEM
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS WITH REAL-WORLD DATA REUSING BRAZILIAN HEALTH SYSTEM DATABASES: A CASE STUDY IN BREAST CANCER
Mar 18, 2026, 21:38 PM -
THE BUDGET IMPACT OF INTRODUCING ZONGERTINIB INTO THE FORMULARY FOR TREATMENT-NAÏVE AND PRETREATED HER2-MUTANT ADVANCED NSCLC IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
ETHICAL AI DEPLOYMENT IN HEOR
Mar 18, 2026, 21:38 PM -
EFFECT OF CHINESE HERBAL MEDICINE COMBINED WITH CONVENTIONAL ANTI-OSTEOPOROTIC MEDICATION ON FRACTURE RISK IN OLDER ADULTS WITH OSTEOPOROSIS: A RETROSPECTIVE COHORT STUDY
Mar 18, 2026, 21:38 PM -
COMPARATIVE EFFECTIVENESS OF SGLT2I, GLP-1, AND METFORMIN ON CARDIOVASCULAR OUTCOMES IN ADULTS WITH SEVERE MENTAL ILLNESS
Mar 18, 2026, 21:38 PM -
BREAKTHROUGH THERAPY (BT) AND FAST TRACK (FT) DESIGNATIONS IN NEW DRUG APPLICATIONS AND BIOLOGIC LICENSE APPLICATIONS (NDAS/BLAS) TO FDA’S CENTER FOR DRUG EVALUATION AND RESEARCH (CDER), 2013-2025
Mar 18, 2026, 21:38 PM -
CHOOSING PUBLIC LLMS AND AI AGENTS FOR PATIENT OUTCOMES RESEARCH: PRACTICAL PROS/CONS AND GOVERNANCE IMPLICATIONS
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS ANALYSIS OF INATICABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IN CHINA
Mar 18, 2026, 21:38 PM -
ARE EVIDENCE REVIEW REQUIREMENTS SIMILAR ACROSS HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES? A CROSS-SECTIONAL STUDY OF NICE, CDA, IQWIG AND EU JCA
Mar 18, 2026, 21:38 PM -
SURVIVING UNANCHORED INDIRECT COMPARISONS: AN EXTENSION OF MULTILEVEL UNANCHORED META-REGRESSION (ML-UMR) FOR SURVIVAL ANALYSES
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT OF FINERENONE IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) AND HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF):IMPLICATIONS FOR U.S. HEALTHCARE DECISION-MAKERS
Mar 18, 2026, 21:38 PM -
HEALTHCARE COST, RESOURCE USE, AND ECONOMIC MODELS OF CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER PATIENTS (MIBC)
Mar 18, 2026, 21:38 PM -
TRENDS IN THE USE OF REAL-WORLD EVIDENCE IN PRESS RELEASES ISSUED BY THE TOP 15 PHARMACEUTICAL COMPANIES
Mar 18, 2026, 21:38 PM -
PROJECT ORBIS: DOES REGULATORY ACCELERATION TRANSLATE TO FASTER GLOBAL PATIENT ACCESS?
Mar 18, 2026, 21:38 PM -
COMPARISON OF SAMPLING STRATEGIES TO ADDRESS SEVERE DATA IMBALANCE AND COMPUTATIONAL BENCHMARKING FOR TIME-TO-EVENT PREDICTIVE MODEL DEVELOPMENT ACROSS LOCAL AND HIGH-PERFORMANCE COMPUTING ENVIRONMENTS: PREDICTION OF ALCOHOL USE DISORDER AND OPIOID...
Mar 18, 2026, 21:38 PM
